LD-2 disclosure · 3rd Quarter - Report
REGENXBIO
Client
- Name
- REGENXBIO
- Description
- Develop innovative therapies to treat patients with rare or otherwise debilitating disease
- Location
- Maryland · United States of America
Registrant
- Description
- Government Relations
- Location
- Arlington, Virginia, United States of America
Lobbying activities
4 issuesHealth Issues
Potential legislation implementing value based purchasing for pharmaceuticals (HR 7389); Possible provisions related to Drug Pricing Legislation that affect biological products' development, approval, accelerated approval, and marketing, including deliberations associated with the Reauthorization of the Prescription Drug User Fee Act ( HR 7667) (S 4348), or the continuing resolution(Further Extendjnf Government Funding Act P.L. 117-70. Possible drug pricing legislation included in any budget reconciliation legislation ( no specific number). Reauthorization of the Newborn Screening Saves Lives Act (HR 482, S 350.)
LobbyistsPATRICIA KNIGHT
Covered position (PATRICIA KNIGHT): Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill. Development of Value Based Purchasing legislation ( HR 7389).
LobbyistsPATRICIA KNIGHT
Covered position (PATRICIA KNIGHT): Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch
TargetedSENATE · HOUSE OF REPRESENTATIVES